Ziel
The Angiolutions device is a first-of-its-kind device stopping the life-threatening progression of small abdominal aortic aneurysm (AAA) – a pathological dilation of the aorta.
Angiolutions’ award-winning & patent-protected solution leverages a fundamentally new understanding of AAA growth discovered by the founders at Stanford University. They showed that stiffness gradients between the compliant (healthy) aorta and the adjacent stiff (diseased) aneurysm serve as a motor for AAA growth.
Based on this principle & together with key physicians, we developed a minimally-invasive, non-active aortic implant (class III). The nitinol-based device is positioned adjacent to the aneurysm sack via simple, catheter-based implantation. It is specifically designed to focally increase aortic stiffness in the compliant AAA neck region, thereby reducing stiffness gradients towards the stiff AAA sack that drive aneurysm growth.Hereby we achieve a fast, low-risk, size-stabilizing treatment of small AAA.
Wissenschaftliches Gebiet
Schlüsselbegriffe
Programm/Programme
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Aufforderung zur Vorschlagseinreichung
HORIZON-EIC-2023-ACCELERATOR-01
Andere Projekte für diesen Aufruf anzeigenFinanzierungsplan
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceKoordinator
30179 HANNOVER
Deutschland
Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen).